{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:28:30Z","timestamp":1784579310332,"version":"3.55.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40256-025-00766-5","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:55:01Z","timestamp":1758815701000},"page":"137-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contemporary Antianginal Therapy"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6670-851X","authenticated-orcid":false,"given":"Sagar","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ayyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthi","family":"Palani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Allencherril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"2","key":"766_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","volume":"15","author":"R Ferrari","year":"2018","unstructured":"Ferrari R, Camici PG, Crea F, et al. A \u201cdiamond\u201d approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120\u201332. https:\/\/doi.org\/10.1038\/nrcardio.2017.131.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"766_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10557-016-6681-2","volume":"30","author":"U Thadani","year":"2016","unstructured":"Thadani U. Management of stable angina\u2014current guidelines: a critical appraisal. Cardiovasc Drugs Ther. 2016;30(4):419\u201326. https:\/\/doi.org\/10.1007\/s10557-016-6681-2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"766_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425.","journal-title":"Eur Heart J"},{"issue":"18","key":"766_CR4","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/jama.2011.601","volume":"305","author":"WB Borden","year":"2011","unstructured":"Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882\u20139. https:\/\/doi.org\/10.1001\/jama.2011.601.","journal-title":"JAMA"},{"issue":"1","key":"766_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/clc.22628","volume":"40","author":"F Kureshi","year":"2016","unstructured":"Kureshi F, Shafiq A, Arnold SV, et al. The prevalence and management of angina among patients with chronic coronary artery disease across US outpatient cardiology practices: insights from the angina prevalence and provider evaluation of angina relief (APPEAR) study. Clin Cardiol. 2016;40(1):6\u201310. https:\/\/doi.org\/10.1002\/clc.22628.","journal-title":"Clin Cardiol"},{"key":"766_CR6","doi-asserted-by":"publisher","unstructured":"Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(17)32714-9.","DOI":"10.1016\/S0140-6736(17)32714-9"},{"issue":"15","key":"766_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/jama.1995.03520390045031","volume":"273","author":"RF Nease Jr","year":"1995","unstructured":"Nease RF Jr, Kneeland T, O\u2019Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina: implications for clinical practice guidelines. JAMA. 1995;273(15):1185\u201390. https:\/\/doi.org\/10.1001\/jama.1995.03520390045031.","journal-title":"JAMA"},{"issue":"9","key":"766_CR8","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","journal-title":"Circulation"},{"issue":"36","key":"766_CR9","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"issue":"20","key":"766_CR10","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","volume":"281","author":"PA Heidenreich","year":"1999","unstructured":"Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927\u201336. https:\/\/doi.org\/10.1001\/jama.281.20.1927.","journal-title":"JAMA"},{"key":"766_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2018.12.008","volume":"283","author":"R Pavasini","year":"2019","unstructured":"Pavasini R, Camici PG, Crea F, et al. Anti-anginal drugs: systematic review and clinical implications. Int J Cardiol. 2019;283:55\u201363. https:\/\/doi.org\/10.1016\/j.ijcard.2018.12.008.","journal-title":"Int J Cardiol"},{"issue":"Suppl 5","key":"766_CR12","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1097\/00005344-199006165-00022","volume":"16","author":"ED de Muinck","year":"1990","unstructured":"de Muinck ED, Lie KI. Safety and efficacy of beta-blockers in the treatment of stable angina pectoris. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S123-128.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"766_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0002-9149(90)91033-3","volume":"65","author":"KA Narahara","year":"1990","unstructured":"Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Am J Cardiol. 1990;65(9):577\u201382. https:\/\/doi.org\/10.1016\/0002-9149(90)91033-3.","journal-title":"Am J Cardiol"},{"key":"766_CR14","doi-asserted-by":"publisher","DOI":"10.5688\/aj710595","author":"ST O\u2019Rourke","year":"2007","unstructured":"O\u2019Rourke ST. Antianginal actions of beta-adrenoceptor antagonists. Am J Pharm Educ. 2007. https:\/\/doi.org\/10.5688\/aj710595.","journal-title":"Am J Pharm Educ"},{"issue":"7","key":"766_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1751-7176.2009.00140.x","volume":"11","author":"C Manrique","year":"2009","unstructured":"Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer \u03b2-blockers for the management of hypertension. J Clin Hypertens. 2009;11(7):369\u201375. https:\/\/doi.org\/10.1111\/j.1751-7176.2009.00140.x.","journal-title":"J Clin Hypertens"},{"issue":"3","key":"766_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1741826711409325","volume":"19","author":"DF Shu","year":"2012","unstructured":"Shu DF, Dong BR, Lin XF, Wu TX, Liu GJ. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol. 2012;19(3):330\u201341. https:\/\/doi.org\/10.1177\/1741826711409325.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"766_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.eurheartj.a014699","volume":"17","author":"KM Fox","year":"1996","unstructured":"Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, TIBET study group. The total ischaemic burden European trial (TIBET): effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J. 1996;17(1):96\u2013103. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a014699.","journal-title":"Eur Heart J"},{"issue":"2","key":"766_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/eurheartj\/ehy504","volume":"40","author":"R Ferrari","year":"2019","unstructured":"Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs\u2013beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40(2):190\u20134. https:\/\/doi.org\/10.1093\/eurheartj\/ehy504.","journal-title":"Eur Heart J"},{"issue":"2","key":"766_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0735-1097(92)90499-D","volume":"19","author":"DT Kawanishi","year":"1992","unstructured":"Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomised individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992;19(2):409\u201317. https:\/\/doi.org\/10.1016\/0735-1097(92)90499-D.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"766_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0167-5273(95)02531-6","volume":"53","author":"JM Walker","year":"1996","unstructured":"Walker JM, Curry PVL, Bailey AE, Steare SE. A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Int J Cardiol. 1996;53(2):117\u201326. https:\/\/doi.org\/10.1016\/0167-5273(95)02531-6.","journal-title":"Int J Cardiol"},{"issue":"15","key":"766_CR21","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","volume":"390","author":"T Yndigegn","year":"2024","unstructured":"Yndigegn T, Lindahl B, Mars K, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024;390(15):1372\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2401479.","journal-title":"N Engl J Med"},{"issue":"1","key":"766_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010150","volume":"14","author":"M Sabina","year":"2024","unstructured":"Sabina M, Shah S, Grimm M, et al. Beta-blockers in patients with myocardial infarction and preserved left ventricular ejection: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2024;14(1):150. https:\/\/doi.org\/10.3390\/jcm14010150.","journal-title":"J Clin Med"},{"key":"766_CR23","unstructured":"Fundaci\u00f3n Centro Nacional de Investigaciones Cardiovasculares Carlos III. TREatment With Beta-Blockers After myOcardial Infarction withOut Reduced Ejection fracTion. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT03596385. Accessed 3 Aug 2025."},{"key":"766_CR24","unstructured":"Atar D. BEtablocker treatment after acute myocardial infarction in patients without reduced left ventricular systolic function (BETAMI). clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT03646357. Accessed 3 Aug 2025."},{"issue":"1","key":"766_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4214-6","volume":"21","author":"AMD Kristensen","year":"2020","unstructured":"Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020;21(1):415. https:\/\/doi.org\/10.1186\/s13063-020-4214-6.","journal-title":"Trials"},{"issue":"5","key":"766_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036284","volume":"7","author":"PG Steg","year":"2012","unstructured":"Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS ONE. 2012;7(5):e36284. https:\/\/doi.org\/10.1371\/journal.pone.0036284.","journal-title":"PLoS ONE"},{"issue":"5","key":"766_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7150\/ijms.18054","volume":"14","author":"J Jiang","year":"2017","unstructured":"Jiang J, Cong H, Zhang Y, et al. Effect of metoprolol succinate in patients with stable angina and elevated heart rate receiving low-dose \u03b2-blocker therapy. Int J Med Sci. 2017;14(5):477\u201383. https:\/\/doi.org\/10.7150\/ijms.18054.","journal-title":"Int J Med Sci"},{"issue":"14","key":"766_CR28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1056\/NEJM197904053001402","volume":"300","author":"U Thadani","year":"1979","unstructured":"Thadani U, Davidson C, Singleton W, Taylor SH. Comparison of the immediate effects of five \u03b2-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979;300(14):750\u20135. https:\/\/doi.org\/10.1056\/NEJM197904053001402.","journal-title":"N Engl J Med"},{"issue":"6","key":"766_CR29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/00005344-199206000-00005","volume":"19","author":"ED de Muinck","year":"1992","unstructured":"de Muinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a multicenter international randomized study of Angina Pectoris (MIRSA). J Cardiovasc Pharmacol. 1992;19(6):870\u20135. https:\/\/doi.org\/10.1097\/00005344-199206000-00005.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"766_CR30","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.ijcard.2012.06.116","volume":"167","author":"PR Kalra","year":"2013","unstructured":"Kalra PR, Morley C, Barnes S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167(6):2695\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2012.06.116.","journal-title":"Int J Cardiol"},{"issue":"Suppl 1","key":"766_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00129784-200707001-00003","volume":"7","author":"WH Frishman","year":"2007","unstructured":"Frishman WH. Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs Drugs Devices Interv. 2007;7(Suppl 1):17\u201323. https:\/\/doi.org\/10.2165\/00129784-200707001-00003.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv."},{"key":"766_CR32","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1097\/00005344-199117001-00018","volume":"17","author":"C Canale","year":"1991","unstructured":"Canale C, Terrachini V, Masperone MA, Caponnetto S. Open comparative study to assess the efficacy and safety of two calcium antagonists: amlodipine and diltiazem in the treatment of symptomatic myocardial ischemia. J Cardiovasc Pharmacol. 1991;17:S57.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"766_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00005344-200109000-00004","volume":"38","author":"K Chugh","year":"2001","unstructured":"Chugh K, Digpal S, Hutchinson K, McDonald T, Miller CJ, Miller AJ, et al. A randomized, double-blind comparison of the efficacy and tolerability of once-daily modified-release diltiazem capsules with once-daily amlodipine tablets in patients with stable angina. J Cardiovasc Pharmacol. 2001;38(3):356.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"766_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0167-5273(97)00261-1","volume":"63","author":"ML De Rosa","year":"1998","unstructured":"De Rosa ML, Giordano A, Melfi M, Guardia DD, Ciaburri F, Rengo F. Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. Int J Cardiol. 1998;63(1):27\u201335. https:\/\/doi.org\/10.1016\/S0167-5273(97)00261-1.","journal-title":"Int J Cardiol"},{"issue":"5, Part 2","key":"766_CR35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0002-8703(89)90845-4","volume":"118","author":"SH Taylor","year":"1989","unstructured":"Taylor SH, Lee P, Jackson N, Cocco G. A four-week double-blind, placebo-controlled, parallel dose-response study of amlodipine in patients with stable exertional angina pectoris. Am Heart J. 1989;118(5, Part 2):1133\u20134. https:\/\/doi.org\/10.1016\/0002-8703(89)90845-4.","journal-title":"Am Heart J"},{"issue":"10","key":"766_CR36","first-page":"1103","volume":"15","author":"CB Toal","year":"1999","unstructured":"Toal CB, Motro M, Baird MG, et al. Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina. Can J Cardiol. 1999;15(10):1103\u20139.","journal-title":"Can J Cardiol"},{"issue":"7","key":"766_CR37","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","volume":"29","author":"H Makani","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate\u2014a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270. https:\/\/doi.org\/10.1097\/HJH.0b013e3283472643.","journal-title":"J Hypertens"},{"issue":"2","key":"766_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00002018-199615020-00002","volume":"15","author":"HT Dougall","year":"1996","unstructured":"Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996;15(2):91\u2013106. https:\/\/doi.org\/10.2165\/00002018-199615020-00002.","journal-title":"Drug Saf"},{"issue":"4","key":"766_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10557-016-6668-z","volume":"30","author":"JM Tarkin","year":"2016","unstructured":"Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. Cardiovasc Drugs Ther. 2016;30(4):367. https:\/\/doi.org\/10.1007\/s10557-016-6668-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl F","key":"766_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/17.suppl_f.30","volume":"17","author":"U Thadani","year":"1996","unstructured":"Thadani U. Secondary preventive potential of nitrates in ischaemic heart disease. Eur Heart J. 1996;17(Suppl F):30\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/17.suppl_f.30.","journal-title":"Eur Heart J"},{"issue":"3","key":"766_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF00266360","volume":"42","author":"LJ Wight","year":"1992","unstructured":"Wight LJ, VandenBurg MJ, Potter CE, Freeth CJ. A large scale comparative study in general practice with nitroglycerin spray and tablet formulations in elderly patients with angina pectoris. Eur J Clin Pharmacol. 1992;42(3):341\u20132. https:\/\/doi.org\/10.1007\/BF00266360.","journal-title":"Eur J Clin Pharmacol"},{"key":"766_CR42","unstructured":"Nitroglycerin spray: uses, side effects, dosage and more. GoodRx. https:\/\/www.goodrx.com\/nitrolingual\/what-is. Accessed 29 Dec 2024."},{"key":"766_CR43","unstructured":"Nitrostat (nitroglycerin sublingual tablets): uses, side effects, warnings and more. GoodRx. https:\/\/www.goodrx.com\/nitroglycerin\/what-is. Accessed 29 Dec 2024."},{"issue":"17","key":"766_CR44","doi-asserted-by":"publisher","first-page":"61G","DOI":"10.1016\/0002-9149(92)90028-w","volume":"70","author":"UW Abshagen","year":"1992","unstructured":"Abshagen UW. Pharmacokinetics of isosorbide mononitrate. Am J Cardiol. 1992;70(17):61G-66G. https:\/\/doi.org\/10.1016\/0002-9149(92)90028-w.","journal-title":"Am J Cardiol"},{"issue":"10","key":"766_CR45","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/000331979704801002","volume":"48","author":"MG Niemeyer","year":"1997","unstructured":"Niemeyer MG, Kleinjans HAJ, de Ree R, et al. Comparison of multiple-dose and once-daily nitrate therapy in 1212 patients with stable angina pectoris: effects on quality of life indices. Angiology. 1997;48(10):855\u201362. https:\/\/doi.org\/10.1177\/000331979704801002.","journal-title":"Angiology"},{"issue":"2","key":"766_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.amjcard.2004.03.067","volume":"94","author":"P Kardas","year":"2004","unstructured":"Kardas P. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am J Cardiol. 2004;94(2):213\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2004.03.067.","journal-title":"Am J Cardiol"},{"issue":"20","key":"766_CR47","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","volume":"113","author":"BR Chaitman","year":"2006","unstructured":"Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.597500.","journal-title":"Circulation"},{"issue":"16","key":"766_CR48","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"DA Morrow","year":"2007","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775\u201383. https:\/\/doi.org\/10.1001\/jama.297.16.1775.","journal-title":"JAMA"},{"issue":"3","key":"766_CR49","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2006.05.044.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"766_CR50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309\u201316. https:\/\/doi.org\/10.1001\/jama.291.3.309.","journal-title":"JAMA"},{"issue":"8","key":"766_CR51","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2003.11.045.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"766_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","volume":"95","author":"MF Rousseau","year":"2005","unstructured":"Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2004.09.025.","journal-title":"Am J Cardiol"},{"issue":"6","key":"766_CR53","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2337\/dc09-2334","volume":"33","author":"JW Chisholm","year":"2010","unstructured":"Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6):1163\u20138. https:\/\/doi.org\/10.2337\/dc09-2334.","journal-title":"Diabetes Care"},{"issue":"5","key":"766_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/1060028017747901","volume":"52","author":"X Zeng","year":"2018","unstructured":"Zeng X, Zhang Y, Lin J, Zheng H, Peng J, Huang W. Efficacy and safety of ranolazine in diabetic patients: a systematic review and meta-analysis. Ann Pharmacother. 2018;52(5):415\u201324. https:\/\/doi.org\/10.1177\/1060028017747901.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"766_CR55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1161\/CIRCULATIONAHA.123.066680","volume":"149","author":"A Sinha","year":"2024","unstructured":"Sinha A, Rahman H, Douiri A, et al. ChaMP-CMD: a phenotype-blinded, randomized controlled, cross-over trial. Circulation. 2024;149(1):36\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066680.","journal-title":"Circulation"},{"issue":"10","key":"766_CR56","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.2337\/db13-1562","volume":"63","author":"AK Dhalla","year":"2014","unstructured":"Dhalla AK, Yang M, Ning Y, et al. Blockade of Na+ channels in pancreatic \u03b1-cells has antidiabetic effects. Diabetes. 2014;63(10):3545\u201356. https:\/\/doi.org\/10.2337\/db13-1562.","journal-title":"Diabetes"},{"key":"766_CR57","unstructured":"Ranolazine (Ranexa): Uses, side effects, dosage and reviews. GoodRx. https:\/\/www.goodrx.com\/ranolazine\/what-is. Accessed 2 Aug 2025."},{"issue":"6","key":"766_CR58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.cir.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G, Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817\u201323. https:\/\/doi.org\/10.1161\/01.cir.0000048143.25023.87.","journal-title":"Circulation"},{"issue":"23","key":"766_CR59","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529\u201336. https:\/\/doi.org\/10.1093\/eurheartj\/ehi586.","journal-title":"Eur Heart J"},{"issue":"2","key":"766_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000439584","volume":"133","author":"K Werdan","year":"2016","unstructured":"Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with metoprolol improves symptoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial. Cardiology. 2016;133(2):83\u201390. https:\/\/doi.org\/10.1159\/000439584.","journal-title":"Cardiology"},{"key":"766_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.exger.2014.09.002","volume":"59","author":"U M\u00fcller-Werdan","year":"2014","unstructured":"M\u00fcller-Werdan U, St\u00f6ckl G, Ebelt H, Nuding S, H\u00f6pfner F, Werdan K. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34\u201341. https:\/\/doi.org\/10.1016\/j.exger.2014.09.002.","journal-title":"Exp Gerontol"},{"issue":"46","key":"766_CR62","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1093\/eurheartj\/ehv451","volume":"36","author":"K Fox","year":"2015","unstructured":"Fox K, Ford I, Steg PG, et al. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J. 2015;36(46):3291\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehv451.","journal-title":"Eur Heart J"},{"issue":"9744","key":"766_CR63","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(10)61198-1.","journal-title":"Lancet"},{"issue":"1","key":"766_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2023.2262073","volume":"11","author":"ZM Khan","year":"2023","unstructured":"Khan ZM, Briere JB, Olewinska E, Khrouf F, Nikodem M. Ivabradine in patients with heart failure: a systematic literature review. J Market Access Health Policy. 2023;11(1):2262073. https:\/\/doi.org\/10.1080\/20016689.2023.2262073.","journal-title":"J Market Access Health Policy"},{"issue":"11","key":"766_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013004.pub2","volume":"2020","author":"C Benstoem","year":"2020","unstructured":"Benstoem C, Kalvelage C, Breuer T, et al. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev. 2020;2020(11):CD013004. https:\/\/doi.org\/10.1002\/14651858.CD013004.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"766_CR66","unstructured":"Ivabradine dosage guide + max dose, adjustments. Drugs.com. https:\/\/www.drugs.com\/dosage\/ivabradine.html. Accessed 2 Aug 2025."},{"issue":"14","key":"766_CR67","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70(14):1777\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.038.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"766_CR68","first-page":"810","volume":"40","author":"S Tse","year":"2015","unstructured":"Tse S, Mazzola N. Ivabradine (Corlanor) for heart failure: the first selective and specific I f inhibitor. P T Peer-Rev J Formul Manag. 2015;40(12):810\u20134.","journal-title":"P T Peer-Rev J Formul Manag"},{"issue":"24","key":"766_CR69","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","volume":"22","author":"H Szwed","year":"2001","unstructured":"Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267\u201374. https:\/\/doi.org\/10.1053\/euhj.2001.2896.","journal-title":"Eur Heart J"},{"issue":"1","key":"766_CR70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00045391-200501000-00006","volume":"12","author":"EI Chazov","year":"2005","unstructured":"Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in angina combination therapy\u2014the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12(1):35\u201342. https:\/\/doi.org\/10.1097\/00045391-200501000-00006.","journal-title":"Am J Ther"},{"issue":"4","key":"766_CR71","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/hrt.78.4.353","volume":"78","author":"SC Manchanda","year":"1997","unstructured":"Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart. 1997;78(4):353\u20137. https:\/\/doi.org\/10.1136\/hrt.78.4.353.","journal-title":"Heart"},{"issue":"10","key":"766_CR72","first-page":"533","volume":"29","author":"H Szwed","year":"2000","unstructured":"Szwed H, Pachocki R, Domzal-Bochenska M, et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Medicale Paris Fr 1983. 2000;29(10):533\u20138.","journal-title":"Presse Medicale Paris Fr 1983"},{"issue":"10254","key":"766_CR73","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","volume":"396","author":"R Ferrari","year":"2020","unstructured":"Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10254):830\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)31790-6.","journal-title":"Lancet"},{"key":"766_CR74","unstructured":"Imbria Pharmaceuticals, Inc. a randomized, double-blind, placebo-controlled, exploratory study on the safety, tolerability, and pharmacodynamics of IMB-1018972 in subjects with angina due to obstructive coronary artery disease. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT04826172. Accessed 28 Jan 2025."},{"key":"766_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.parkreldis.2019.01.005","volume":"62","author":"D Pint\u00e9r","year":"2019","unstructured":"Pint\u00e9r D, Kov\u00e1cs M, Harmat M, Juh\u00e1sz A, Janszky J, Kov\u00e1cs N. Trimetazidine and parkinsonism: a prospective study. Parkinsonism Relat Disord. 2019;62:117\u201321. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.01.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"766_CR76","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/pds.4675","volume":"27","author":"D von Bredow","year":"2018","unstructured":"von Bredow D, Toussi M, Samad A, et al. Evaluation of the effectiveness of risk minimization measures for trimetazidine: a cross sectional joint PASS survey among physicians in selected European countries. Pharmacoepidemiol Drug Saf. 2018;27(12):1385\u201392. https:\/\/doi.org\/10.1002\/pds.4675.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"766_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0735-1097(01)01708-9","volume":"39","author":"AJ Maxwell","year":"2002","unstructured":"Maxwell AJ, Zapien MP, Pearce GL, MacCallum G, Stone PH. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol. 2002;39(1):37\u201345. https:\/\/doi.org\/10.1016\/s0735-1097(01)01708-9.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"766_CR78","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0735-1097(01)01380-8","volume":"38","author":"HA Walker","year":"2001","unstructured":"Walker HA, McGing E, Fisher I, et al. Endothelium-dependent vasodilation is independent of the plasma l-arginine\/ADMA ratio in men with stable angina: lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol. 2001;38(2):499\u2013505. https:\/\/doi.org\/10.1016\/S0735-1097(01)01380-8.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"766_CR79","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/01.cir.101.18.2160","volume":"101","author":"A Blum","year":"2000","unstructured":"Blum A, Hathaway L, Mincemoyer R, et al. Oral l-arginine in patients with coronary artery disease on medical management. Circulation. 2000;101(18):2160\u20134. https:\/\/doi.org\/10.1161\/01.cir.101.18.2160.","journal-title":"Circulation"},{"issue":"7","key":"766_CR80","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.amjcard.2003.12.040","volume":"93","author":"A Palloshi","year":"2004","unstructured":"Palloshi A, Fragasso G, Piatti P, et al. Effect of oral l-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol. 2004;93(7):933\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2003.12.040.","journal-title":"Am J Cardiol"},{"issue":"9","key":"766_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092880","volume":"9","author":"F Vancheri","year":"2020","unstructured":"Vancheri F, Longo G, Vancheri S, Henein M. Coronary microvascular dysfunction. J Clin Med. 2020;9(9):2880. https:\/\/doi.org\/10.3390\/jcm9092880.","journal-title":"J Clin Med"},{"issue":"14","key":"766_CR82","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.118.031373","volume":"138","author":"JC Kaski","year":"2018","unstructured":"Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of ischemic heart disease. Circulation. 2018;138(14):1463\u201380. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.031373.","journal-title":"Circulation"},{"issue":"7","key":"766_CR83","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023207","volume":"11","author":"N Mileva","year":"2022","unstructured":"Mileva N, Nagumo S, Mizukami T, et al. Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc. 2022;11(7):e023207. https:\/\/doi.org\/10.1161\/JAHA.121.023207.","journal-title":"J Am Heart Assoc"},{"issue":"23, Part A","key":"766_CR84","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","volume":"72","author":"TJ Ford","year":"2018","unstructured":"Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72(23, Part A):2841\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.006.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"766_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041129","volume":"11","author":"A Marrone","year":"2022","unstructured":"Marrone A, Pavasini R, Scollo E, et al. Acetylcholine use in modern cardiac catheterization laboratories: a systematic review. J Clin Med. 2022;11(4):1129. https:\/\/doi.org\/10.3390\/jcm11041129.","journal-title":"J Clin Med"},{"issue":"44","key":"766_CR86","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3238\/arztebl.m2023.0205","volume":"120","author":"H Ullrich-Daub","year":"2023","unstructured":"Ullrich-Daub H, Daub S, Olschewski M, M\u00fcnzel T, Gori T. Diseases of the coronary microcirculation: diagnosis and treatment. Dtsch Arztebl Int. 2023;120(44):739. https:\/\/doi.org\/10.3238\/arztebl.m2023.0205.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"766_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","volume":"112","author":"A Villano","year":"2013","unstructured":"Villano A, Franco AD, Nerla R, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013;112(1):8\u201313. https:\/\/doi.org\/10.1016\/j.amjcard.2013.02.045.","journal-title":"Am J Cardiol"},{"issue":"19","key":"766_CR88","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","volume":"37","author":"CN Bairey Merz","year":"2016","unstructured":"Bairey Merz CN, Handberg EM, Shufelt CL, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016;37(19):1504\u201313. https:\/\/doi.org\/10.1093\/eurheartj\/ehv647.","journal-title":"Eur Heart J"},{"key":"766_CR89","doi-asserted-by":"publisher","first-page":"11495","DOI":"10.1038\/srep11495","volume":"5","author":"CC Lee","year":"2015","unstructured":"Lee CC, Chang SS, Lee SH, Chen YS, Hsu WT, Gabriel Lee MT. Use of nicorandil is associated with increased risk for gastrointestinal ulceration and perforation- a nationally representative population-based study. Sci Rep. 2015;5:11495. https:\/\/doi.org\/10.1038\/srep11495.","journal-title":"Sci Rep"},{"issue":"7","key":"766_CR90","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/2047487314533217","volume":"22","author":"J Belsey","year":"2015","unstructured":"Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(7):837\u201348. https:\/\/doi.org\/10.1177\/2047487314533217.","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"766_CR91","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","volume":"382","author":"DJ Maron","year":"2020","unstructured":"Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1915922.","journal-title":"N Engl J Med"},{"key":"766_CR92","doi-asserted-by":"publisher","first-page":"44789","DOI":"10.1038\/srep44789","volume":"7","author":"X Yang","year":"2017","unstructured":"Yang X, Li Y, Ren X, et al. Effects of exercise-based cardiac rehabilitation in patients after percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Sci Rep. 2017;7:44789. https:\/\/doi.org\/10.1038\/srep44789.","journal-title":"Sci Rep"},{"key":"766_CR93","unstructured":"NYU Langone Health. mHealth-CArdiac REhabilitation for INOCA (INOCA-CARE). clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT06829160. Accessed 2 Aug 2025."},{"issue":"1","key":"766_CR94","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1161\/CIR.0000000000001150","volume":"148","author":"JR Golbus","year":"2023","unstructured":"Golbus JR, Lopez-Jimenez F, Barac A, et al. Digital technologies in cardiac rehabilitation: a science advisory from the American Heart Association. Circulation. 2023;148(1):95\u2013107. https:\/\/doi.org\/10.1161\/CIR.0000000000001150.","journal-title":"Circulation"},{"key":"766_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03402-9","volume":"23","author":"B Huang","year":"2023","unstructured":"Huang B, Han X, Pan Y, Chen D. A systematic review and meta-analysis of the effect of high-intensity statin on coronary microvascular dysfunction. BMC Cardiovasc Disord. 2023;23:370. https:\/\/doi.org\/10.1186\/s12872-023-03402-9.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"766_CR96","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/archinte.166.7.787","volume":"166","author":"N Danchin","year":"2006","unstructured":"Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med. 2006;166(7):787\u201396. https:\/\/doi.org\/10.1001\/archinte.166.7.787.","journal-title":"Arch Intern Med"},{"key":"766_CR97","doi-asserted-by":"publisher","unstructured":"Abouzid MR, Eldahtoury S, Elshafei SM, et al. Efficacy of angiotensin-converting enzyme inhibitors in coronary microvascular dysfunction: a systematic review and meta-analysis of randomized clinical trials. Cureus. 16(1):e52684. https:\/\/doi.org\/10.7759\/cureus.52684.","DOI":"10.7759\/cureus.52684"},{"key":"766_CR98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ahj.2021.03.011","volume":"237","author":"EM Handberg","year":"2021","unstructured":"Handberg EM, Merz CNB, Cooper-Dehoff RM, et al. Rationale and design of the Women\u2019s Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J. 2021;237:90\u2013103. https:\/\/doi.org\/10.1016\/j.ahj.2021.03.011.","journal-title":"Am Heart J"},{"issue":"7","key":"766_CR99","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0735-1097(99)00140-0","volume":"33","author":"RR Arora","year":"1999","unstructured":"Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833\u201340. https:\/\/doi.org\/10.1016\/S0735-1097(99)00140-0.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"766_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-086901","volume":"14","author":"F Cao","year":"2024","unstructured":"Cao F, Liu Y, Wei W, Liang J. Effect of enhanced external counterpulsation on coronary microcirculation dysfunction (CMD) in patients with coronary artery disease (EECP-CMD II): study protocol of a single-centre, open-label, parallel group, randomised controlled trial. BMJ Open. 2024;14(8):e086901. https:\/\/doi.org\/10.1136\/bmjopen-2024-086901.","journal-title":"BMJ Open"},{"issue":"10","key":"766_CR101","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.jacc.2005.06.079","volume":"46","author":"MB Leon","year":"2005","unstructured":"Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46(10):1812\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2005.06.079.","journal-title":"J Am Coll Cardiol"},{"key":"766_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003712.pub3","author":"E Briones","year":"2015","unstructured":"Briones E, Lacalle JR, Marin-Leon I, Rueda JR. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD003712.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"34","key":"766_CR103","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1093\/eurheartj\/ehz915","volume":"41","author":"TJ Ford","year":"2020","unstructured":"Ford TJ, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. Eur Heart J. 2020;41(34):3239. https:\/\/doi.org\/10.1093\/eurheartj\/ehz915.","journal-title":"Eur Heart J"},{"issue":"2","key":"766_CR104","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10557-016-6641-x","volume":"30","author":"K Liou","year":"2016","unstructured":"Liou K, Jepson N, Buckley N, et al. Design and rationale for the endothelin-1 receptor antagonism in the prevention of microvascular injury in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention (ENDORA-PCI) trial. Cardiovasc Drugs Ther. 2016;30(2):169\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6641-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"766_CR105","unstructured":"Berry C. The effect of mineralocorticoid receptor antagonist therapy in patients with acute myocardial infection or injury and cardiovascular risk factors: a registry-based, stratified-medicine, randomised, controlled trial. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT05198791. Accessed 23 Jan 2025."},{"issue":"24","key":"766_CR106","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.jcin.2024.09.018","volume":"17","author":"D Tryon","year":"2024","unstructured":"Tryon D, Corban MT, Alkhouli M, et al. Coronary sinus reducer improves angina, quality of life, and coronary flow reserve in microvascular dysfunction. JACC Cardiovasc Interv. 2024;17(24):2893\u2013904. https:\/\/doi.org\/10.1016\/j.jcin.2024.09.018.","journal-title":"JACC Cardiovasc Interv"},{"key":"766_CR107","unstructured":"Shockwave Medical, Inc. Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT05102019. Accessed 15 Mar 2025."},{"key":"766_CR108","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.124.014054","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Henry TD, Traverse JH, et al. Angiogenic gene therapy for refractory angina: results of the EXACT phase 2 trial. Circ Cardiovasc Interv. 2024. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.124.014054.","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"766_CR109","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/eurheartj\/ehx764","volume":"39","author":"TD Henry","year":"2018","unstructured":"Henry TD, Losordo DW, Traverse JH, et al. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J. 2018;39(23):2208\u201316. https:\/\/doi.org\/10.1093\/eurheartj\/ehx764.","journal-title":"Eur Heart J"},{"key":"766_CR110","unstructured":"BioCardia, Inc. Randomized controlled pivotal trial of autologous bone marrow cells using the CardiAMP cell therapy system in patients with refractory angina pectoris and chronic myocardial ischemia (CardiAMP CMI Trial). clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT03455725. Accessed 29 Jan 2025."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00766-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00766-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00766-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:24:04Z","timestamp":1771507444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00766-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00766-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sagar Patel, Vishal Patel, Arthi Palani, Mohammed Ayyad, and Joseph Allencherril declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sagar Patel: conceptualization, methodology, investigation, writing\u2014original draft, writing\u2014review and editing, and visualization. Vishal Patel: investigation and writing\u2014review and editing. Arthi Palani: investigation and writing\u2014review and editing. Mohammed Ayyad: investigation and writing\u2014review and editing. Joseph Allencherril: conceptualization, supervision, writing\u2014review and editing, and project administration.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}